

### **Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:1 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No: PTA-2330;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: PTA-2330;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: PTA-2330;

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: PTA-2330;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: PTA-2330 having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:1;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:1;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:2;  
and

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2-10. (Canceled)

11. (Original) An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA-2330;

(b) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA-2330 having biological activity;

(c) a polypeptide domain of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA-2330;

(d) a polypeptide epitope of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA-2330;

(e) a mature form of a secreted protein;

(f) a full length secreted protein;

(g) a variant of SEQ ID NO:2;

(h) an allelic variant of SEQ ID NO:2; and

(i) a species homologue of the SEQ ID NO:2.

12-17. (Canceled)

18. (Original) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject related to expression or activity of a secreted protein comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. (Original) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject related to expression or activity of a secreted protein comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. (Original) A method for identifying binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. (Canceled)

22. (Original) A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO:1 in a cell;
- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. (Canceled)

24. (New) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

- (a) a protein consisting of amino acid residues 1 to 174 of SEQ ID NO:2;
- (b) a protein consisting of a portion of SEQ ID NO:2, wherein said portion comprises at least 30 contiguous amino acid residues of SEQ ID NO:2; and
- (c) a protein consisting of a portion of SEQ ID NO:2, wherein said portion comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.

25. (New) The antibody or fragment thereof of claim 24 that specifically binds protein (a).

26. (New) The antibody or fragment thereof of claim 24 that specifically binds protein (b).

27. (New) The antibody or fragment thereof of claim 24 that specifically binds protein (c).

28. (New) The antibody or fragment thereof of claim 24 which is a human antibody.

29. (New) The antibody or fragment thereof of claim 24 which is a polyclonal antibody.

30. (New) The antibody or fragment thereof of claim 24 which is a monoclonal antibody.

31. (New) The antibody or fragment thereof of claim 24 which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) a Fab fragment.

32. (New) The antibody or fragment thereof of claim 24 which is labeled.

33. (New) The antibody or fragment thereof of claim 32 wherein the label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label;
- (c) a luminescent label; and

(d) a bioluminescent label.

34. (New) The antibody or fragment thereof of claim 24 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

35. (New) The antibody or fragment thereof of claim 24 wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.

36. (New) An isolated cell that produces the antibody or fragment thereof of claim 24.

37. (New) A hybridoma that produces the antibody or fragment thereof of claim 24.

38. (New) A method of detecting PGRP-L protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or fragment thereof of claim 24; and

(b) detecting the PGRP-L protein in the biological sample.

39. (New) The method of claim 38 wherein the antibody or fragment thereof is a polyclonal antibody.